INTRODUCTION
Current understanding on the pharmacokinetics of drugs in neonates with hypoxic ischemic encephalopathy (HIE) is limited. In addition to brain injury, global hypoxic insult often results in acute liver and kidney injury that can impact drug clearance (CL). [1] [2] [3] [4] [5] In addition, therapeutic hypothermia is recommended for moderate-to-severe HIE 6 with the potential to alter drug pharmacokinetics through changes in organ physiology and blood flow. 7 Considering these factors, drug pharmacokinetics must be evaluated in neonates with HIE receiving hypothermia. 7 Gentamicin is commonly used in neonates with HIE for the empiric treatment of presumptive infection. 7 A previous study demonstrated no impact of hypothermia on trough concentrations in HIE neonates. 8 However, in this same study a gentamicin dose of 4-5 mg kg À 1 every 24 h resulted in elevated trough concentrations, that is, 42 mg l À 1 in 36% of hypothermic and 44% of normothermic neonates. A population pharmacokinetic analysis of gentamicin in neonates with HIE receiving hypothermia also reported frequent elevations in trough concentrations using a similar dosing scheme. 9 A dosing interval of every 36 h was predicted to be needed to allow for adequate drug CL and achieve target trough concentrations o2 mg l À 1 . Accordingly, our institution recently changed the empiric dose of gentamicin for neonates with HIE receiving hypothermia from 5 mg kg À 1 every 24 h to 5 mg kg every 36 h. The aim of this study was to evaluate the impact of this change in dosing frequency on target drug concentration achievement.
METHODS
This study was approved by the UCSF Committee on Human Research. In January 2011, the neonatal intensive care unit (a 50-bed level III unit located in a tertiary care, academic medical center) at the University of California, San Francisco (UCSF) adopted a revised empirical gentamicin dose of 5 mg kg À 1 intravenously every 36 h for neonates with HIE receiving therapeutic hypothermia. Before this time, the recommended gentamicin dose was 5 mg kg À 1 intravenously every 24 h. Using retrospective chart review, the initial gentamicin peak and trough concentrations in the study population (neonates with HIE treated with whole-body therapeutic hypothermia (33.5 1C)) pre-and postimplementation of the every 36-h dosing regimen were evaluated. The evaluation time periods were the following: November 2007 to March 2010 (gentamicin 5 mg kg are disseminated at UCSF using an antimicrobial dosing card distributed to all residents, clinical pharmacists and faculty physicians. Dose recommendations are reinforced by clinical pharmacists via daily review. As part of standard therapeutic drug monitoring (TDM), a trough concentration was recommended after the second or third dose during both treatment periods. Peak concentrations were not recommended during the Q24 h period, but were recommended during the Q36 h period because of the inexperience with the new dose. In those instances associated with acute renal failure (that is, elevated or rapidly rising serum creatinine (Cr)), TDM was occasionally measured earlier than usually recommended. Gentamicin peak concentrations were drawn 30 min after the end of a 30-min infusion, and trough concentrations were drawn just before the next dose.
Clinical and laboratory data, including the complete gentamicin dosing and drug concentration history, were collected. Neonates were excluded if the gentamicin dose or drug concentration history were not available or incomplete, extracorporeal membrane oxygenation was required, or with the presence of concomitant congenital heart disease or kidney disease. The target trough concentration was o2 mg l À 1 . Gentamicin concentrations were measured using a competitive immunoassay with a reportable range of 0.2 to 24 mg l À 1 (ADVIA Centaur Gentamicin assay, Bayer Diagnostics, Deerfield, IL, USA).
Pharmacokinetic and statistical analysis Differences in peak and trough concentrations between treatment periods were compared using Student's t-test. The percentage of neonates achieving target trough concentrations was compared using Fisher's exact test. To examine if gentamicin CL was similar between treatment periods and not confounding drug concentration achievement, an empirical Bayesian estimate of CL was calculated for each neonate implementing our published population pharmacokinetic model 9 in the nonlinear mixedeffects modeling program NONMEM (Version VII; Icon Development Solutions, Ellicott City, MD, USA). In the pharmacokinetic model, gentamicin CL was predicted by birthweight and serum Cr on day of life 2 as defined by the following equation:
The interindividual variability of CL followed an exponential error model with a coefficient of variation of 16.1%. Utilizing each neonate's birthweight, serum Cr, and gentamicin dosing and concentration history, individual empirical Bayesian estimates of CL were calculated using the MAXEVAL ¼ 0 POSTHOC estimation routine in NONMEM. The estimated gentamicin CL was then scaled using the allometric 3/4 power model to a 70 kg adult 11 and log-transformed before comparison by Student's t-test. All statistical analyses were performed using R (Version 2.12.0; R Foundation for Statistical Computing, Vienna, Austria). Continuous data are reported as mean ± s.d., and categorical data are reported as counts (%). A P-value o0.05 was considered significant.
RESULTS
Thirty-four neonates with HIE receiving therapeutic hypothermia in the Q24 h period and 27 neonates with HIE receiving therapeutic hypothermia in the Q36 h period had gentamicin concentration data available. Five neonates were excluded from the Q24 h period: three required extracorporeal membrane oxygenation, one was diagnosed with cardiomyopathy and one had incomplete dose records. Four neonates were excluded from the Q36 h period: one required extracorporeal membrane oxygenation, two had incomplete dose records and one had only a random drug level. Therefore, a total of 29 neonates in the Q24 h period and 23 neonates in the Q36 h period were evaluated. All neonates had gentamicin trough concentrations available. Eighteen (62%) neonates in the Q24 h period and 20 (87%) neonates in the Q36 h period had peak concentrations.
Neonates were generally comparable between the two treatment periods; however, neonates in the Q24 h period had a slightly lower gestational age, lower 5-min APGAR, higher base deficit and higher mortality rate (Table 1) . Five neonates died after redirection of care for severe brain injury that was detected by neurologic exam and confirmed with electroencephalography and/or head ultrasound and magnetic resonance imaging. One neonate died after redirection of care for moderate-to-severe brain injury and severe end-organ dysfunction represented by persistent coagulopathy requiring ongoing transfusions, elevated liver enzymes and acute renal failure. There were no differences in birthweight and serum Cr between treatment periods-two major predictors of gentamicin CL.
The mean gentamicin dose was 4.9 ± 0.3 mg kg À 1 every 24 h and 5.0 ± 0.1 mg kg À 1 every 36 h during the Q24 and Q36 h period, respectively. The time of initial gentamicin drug level measurement increased from 2.2±1.1 days in the Q24 period to 3.2 ± 0.9 days in the Q36 period (P ¼ 0.001). This increase coincides with the difference in timing of a third gentamicin dose using an every 24 h vs an every 36 h regimen. Gentamicin peak and trough concentrations achieved during both treatment periods are shown in Figure 1 . The mean trough concentration decreased from 2.0 ± 0.8 mg l À 1 in the Q24 h period to 0.9 ± 0.4 mg l À 1 in the Q36 h period (Po0.001). The percentage of neonates with an On day of life two; three patients in Q24 h group did not have serum creatinine.
Every 36-h gentamicin dosing in HIE neonates A Frymoyer et al elevated trough concentration 42 mg l À 1 decreased from 38% (11 of 29) to 4% (1 of 23) with implementation of a Q36-h dosing interval (Po0.007). There was a trend toward lower peak concentrations (Q24 h 11.4 ± 2.3 mg l À 1 vs Q36 h 10.0 ± 1.9 mg l À 1 ; P ¼ 0.05). The lowest peak concentration was 7.5 and 7.4 mg l À 1 in the Q24 and Q36 h periods, respectively. Gentamicin CL was similar in both treatment periods (Q24 h 1.17 ± 0.24 l h À 1 per 70 kg vs Q36 h 1.15 ± 0.19 l À 1 h per 70 kg; P ¼ 0.9). Serum Cr on the second day of life correlated with trough concentration (Q24 h r 2 ¼ 0.54; Q36 h r 2 ¼ 0.14) and gentamicin CL (combined r 2 ¼ 0.48) (Figure 2 ). During the Q24 period, four of the six neonates who ultimately died had an elevated trough concentration 42 mg l À 1 ; the serum Cr was X1.2 mg dl À 1 in three of these four neonates. In the two neonates who died but had a normal trough concentration, the serum Cr was p0.9 mg dl À 1 on the second day of life. The one neonate who did not achieve target trough concentration in the Q36 h period had a serum Cr of 1.3 mg dl À 1 on the second day of life.
DISCUSSION
This study examined the impact of implementing a new empiric gentamicin dose of 5 mg kg À 1 every 36 h on drug concentrations in neonates with HIE receiving hypothermia. The major study finding was that every 36 h dosing significantly improved achievement of target trough concentration with 96% achieving a concentration o2 mg l À 1 . In addition, high peak concentrations were still maintained with this dosing strategy.
Neonates with HIE are a critically ill population often with multiorgan system morbidity. 3, 4 Therapeutic hypothermia for 72 h is an effective treatment modality in neonates with moderate-tosevere HIE 12 and is now the standard of care. 6 As the treatment for neonates with HIE evolves and specialized neonatal neurocritical care models are developed, 13 understanding the therapeutic use of drugs in this population and their unique clinical pharmacologic needs will be essential.
Gentamicin is a common antibiotic used in neonates to treat suspected sepsis.
14 A standard dose of 4-5 mg kg À 1 every 24 h regularly achieves target drug concentrations in full-term neonates. 15 However, a previous clinical study in neonates with HIE showed a high rate of elevated trough concentrations 42 mg l À 1 for both hypothermic and normothermic subjects when this standard dose was used. 8 To help develop a customized gentamicin dose strategy for neonates with HIE receiving hypothermia, we previously evaluated gentamicin pharmacokinetics. 9 Gentamicin CL was reduced in neonates with HIE receiving hypothermia, and birthweight and serum Cr were significant predictors of gentamicin CL. Monte Carlo simulations predicted a gentamicin dose of 5 mg kg À 1 every 36 h would achieve trough concentrations o2 mg l À 1 in 90% of neonates. Postimplementation of this gentamicin dose, achievement of target trough concentrations in neonates with HIE receiving hypothermia was similar to the model predictions. In addition, this dosing strategy still benefits from higher peak concentrations associated with extended interval aminoglycoside dosing that are desirable given the concentration-dependent killing of gentamicin. 16 While larger, multicenter studies would provide further validation, the current evidence supports an empiric gentamicin dose of 5 mg kg À 1 every 36 h in neonates with HIE receiving hypothermia to achieve trough concentrations o2 mg l À 1 . Gentamicin is eliminated from the body by glomerular filtration, 17 and gentamicin CL was lower in neonates with reduced kidney function as measured by serum Cr on day of life 2 ( Figure 2 ). This is in agreement with previous pharmacokinetic studies in neonates; [18] [19] [20] however, the relationship between serum Cr and gentamicin CL in neonates has been inconsistent. 21 This inconsistency is likely due to the confounding of serum Cr in the first 24 to 48 h after birth with maternal kidney function due placental transfer. However, neonates with HIE who develop acute kidney injury have been documented to have elevation in serum Cr as soon as day of life 1, 22 which could explain its predictive ability found in our study. However, even for a given serum Cr interpatient variation in gentamicin CL remained. Therefore, TDM at the third-gentamicin dose is still necessary to help guide more long-term dosing. Owing to the poor sensitivity of serum Cr in detecting mild and moderate acute kidney injury, 23 newer urinary biomarkers such as neutrophil gelatinase-associated lipocalin that are potentially more sensitive and specific predictors of acute kidney injury warrant further study in the HIE population. [24] [25] [26] We focused on gentamicin dosing in the context of hypothermia since all neonates with HIE in our study were cooled. Animal studies have shown a decrease in gentamicin CL during severe (29 1C) 27 but not moderate (35 1C) hypothermia. 28 A previous clinical study reported similar gentamicin trough concentrations in normothermic and hypothermic (33.5 1C) neonates. 8 A similar lack of effect of hypothermia on drug CL in neonates with HIE has been reported for phenobarbital, a drug primarily dependent upon hepatic metabolism. 29, 30 However, the power to detect small to modest effects of hypothermia on phenobarbital pharmacokinetics was likely low given study design limitations inherent to the HIE population, including small sample size, limited concentration sampling, concomitant medications and large variation in pathophysiology. In addition, an already reduced drug CL in neonates with HIE 31 likely makes the detection of further alterations from hypothermia challenging. Hypothermia is now standard of care in neonates with HIE, 6 and this creates a complexity moving forward in studying the specific effect of hypothermia on drug pharmacokinetics. Whether future studies will be able to address adequately the hypothermic effect on drug pharmacokinetics in neonates is unclear. Nonetheless, understanding drug pharmacokinetics and drug dose needs in neonates with HIE while receiving hypothermia is still valuable clinically.
Limitations to our study include potential differences in neonates between the two study periods. The institution's cooling protocol criteria did not differ between treatment periods and therefore provided some consistency in population selection. Nonetheless, a few measured patient characteristics that could indicate a sicker population were different (see Table 1 ). Most evident, death was more common in the Q24 h period (6 of 29) vs the Q36 h period (0 of 23). However, death was caused by redirection of care for brain injury and not end-organ dysfunction in all but one neonate. In addition, the similarity in birthweight and serum Cr between treatment periods was reassuring since these were found to be two predictors of gentamicin CL in neonates with HIE receiving hypothermia, 9 and the calculated gentamicin CL was the same between treatment periods.
As gentamicin CL is the fundamental pharmacokinetic parameter influencing trough concentrations, the neonates were comparable from a pharmacologic perspective. Furthermore, in the neonates who ultimately died, the serum Cr was still helpful in predicting gentamicin CL and helped differentiate the patients from a pharmacologic perspective. Further limitations to the study include the retrospective design, small sample size and the availability of a convenience sample of drug level data collected as part of routine care. In addition, the study lacked power to evaluate directly the impact of the dose change on clinical outcomes, including treatment effectiveness or toxicity. Every 36-and 48-h dosing intervals have previously been described for other neonatal populations with reduced gentamicin CL such as the preterm neonate. 32, 33 CONCLUSIONS Compared with a 5 mg kg À 1 every 24 h dose, an empiric gentamicin dose of 5 mg kg À 1 every 36 h improved achievement of trough concentrations o2 mg l À 1 in neonates with HIE receiving hypothermia. Owing to the variation and frequent acute kidney injury in neonates with HIE, routine TDM is recommended to help guide dosing. Focused clinical pharmacology studies for other medications commonly used in neonates with HIE receiving hypothermia are warranted.
